Citi Maintains a Buy Rating on Eli Lilly and Company (LLY), Retains the $1,190 PT

Core Viewpoint - Eli Lilly and Company (NYSE: LLY) is currently considered one of the best drug stocks to buy, with a maintained Buy rating and a price target of $1,190.00 by Citi analyst Geoff Meacham [1][2]. Group 1: Company Performance and Outlook - The optimistic outlook for Eli Lilly is supported by the promising results of its obesity treatment, tirzepatide, which received the highest cost-effectiveness rating in a recent draft report by ICER [2]. - Tirzepatide demonstrates superior efficacy in weight loss compared to lifestyle modifications alone, which is expected to enhance payer coverage and improve access to the drug as the value of weight loss and cardiovascular benefits gains recognition [3]. Group 2: Company Overview - Eli Lilly develops, manufactures, discovers, and sells pharmaceutical products across various therapeutic areas, including oncology, diabetes, immunology, and neuroscience [3].